Key Events This Week
16 Mar: Stock opens at Rs.2,091.90, down 2.14%
19 Mar: New 52-week low of Rs.2,010.1 amid sharp decline
20 Mar: Further 52-week low at Rs.1,985.3 and technical downgrade
20 Mar: Week closes at Rs.1,999.75, down 6.45% for the week
16 March 2026: Weak Start Amid Broader Market Gains
Mankind Pharma began the week on a weak note, closing at Rs.2,091.90, down 2.14% from the previous close. This decline occurred despite the Sensex gaining 0.47% to 33,673.11, indicating early signs of stock-specific selling pressure. The relatively low volume of 9,917 shares traded suggested cautious investor sentiment. The stock’s underperformance contrasted with the broader market’s positive tone, foreshadowing a challenging week ahead.
17 March 2026: Continued Decline on Heavy Volume
The downward trend persisted on 17 March, with the stock falling another 1.17% to close at Rs.2,067.45. Notably, trading volume surged to 81,271 shares, reflecting increased selling interest. Meanwhile, the Sensex rose 0.79% to 33,940.18, further highlighting the stock’s divergence from market direction. This day’s activity suggested mounting pressure on Mankind Pharma’s shares amid a generally bullish market backdrop.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
18 March 2026: Brief Rebound Amid Market Rally
On 18 March, Mankind Pharma’s shares rebounded by 1.69%, closing at Rs.2,102.40. This recovery coincided with a strong Sensex rally of 1.15% to 34,329.13, suggesting some short-term relief for the stock. However, the volume remained subdued at 5,638 shares, indicating limited conviction behind the bounce. Despite this uptick, the stock remained below key moving averages, signalling that the broader downtrend was intact.
19 March 2026: Sharp Decline to 52-Week Low Amid Market Weakness
Mankind Pharma experienced a significant setback on 19 March, falling 4.81% to close at Rs.2,001.25 and hitting a new 52-week low of Rs.2,010.1 intraday. This decline outpaced the Pharmaceuticals & Biotechnology sector’s 2.22% fall and the Sensex’s 3.45% drop to 33,255.16. The stock’s underperformance was driven by a combination of weak financial metrics, including a half-year ROCE of 12.33% and declining profitability, alongside bearish technical indicators such as trading below all major moving averages. The intraday low underscored intense selling pressure and heightened investor caution.
20 March 2026: Further 52-Week Low and Technical Downgrade
The downward momentum extended into 20 March, with the stock closing at Rs.1,999.75, down 0.07% on the day and marking a fresh 52-week low of Rs.1,985.3. Despite the Sensex rebounding 0.51% to 33,423.61, Mankind Pharma’s shares remained under pressure. Technical indicators deteriorated further, prompting a downgrade in the Mojo Grade to Sell with a score of 38.0. Bearish moving averages, Bollinger Bands, and volume trends signalled sustained downside risk. The stock’s valuation premium relative to peers, combined with flat recent results and declining debtor turnover, contributed to the cautious outlook.
Holding Mankind Pharma Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Weekly Price Performance: Mankind Pharma vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-16 | Rs.2,091.90 | -2.14% | 33,673.11 | +0.47% |
| 2026-03-17 | Rs.2,067.45 | -1.17% | 33,940.18 | +0.79% |
| 2026-03-18 | Rs.2,102.40 | +1.69% | 34,329.13 | +1.15% |
| 2026-03-19 | Rs.2,001.25 | -4.81% | 33,255.16 | -3.13% |
| 2026-03-20 | Rs.1,999.75 | -0.07% | 33,423.61 | +0.51% |
Key Takeaways
Negative Signals: The stock’s 6.45% weekly decline significantly outpaced the Sensex’s 0.28% fall, reflecting company-specific challenges. Two consecutive 52-week lows and a downgrade to a Sell Mojo Grade underscore bearish momentum. Financial metrics such as a low half-year ROCE of 12.33%, declining debtor turnover ratio of 7.13 times, and an elevated enterprise value to capital employed ratio of 4.3 times raise valuation concerns. Technical indicators, including bearish moving averages and Bollinger Bands, reinforce the downtrend.
Positive Aspects: Despite recent pressures, Mankind Pharma maintains strong long-term net sales growth at 18.21% annually and operating profit growth of 18.72%. The company’s management efficiency remains robust with a ROCE of 25.78%, and its debt servicing capacity is solid, evidenced by a low Debt to EBITDA ratio of 0.54 times. Institutional holdings at 24.59% suggest continued confidence from well-resourced investors.
Conclusion
Mankind Pharma Ltd’s share price performance over the week ending 20 March 2026 reflects a challenging environment marked by sustained selling pressure and technical deterioration. The stock’s fall to fresh 52-week lows and downgrade to a Sell rating highlight near-term risks, while valuation premiums and flat recent financial results add to investor caution. Nonetheless, the company’s strong long-term growth fundamentals and prudent financial management provide some counterbalance. Investors should monitor key support levels and technical indicators closely as the stock navigates this difficult phase.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
